natgillin/translations-raw huggingface dataset:
To prevent deep vein thrombosis and pulmonary embolism from reoccurring, the recommended dose is 2.5 mg twice a day.
Za preprečevanje ponovnega pojava globoke venske tromboze in pljučne embolije je priporočeni odmerek 2,5 mg dvakrat na dan.
to prevent heartworm disease in cats and dogs,
preprečevanje obolenj pri mačkah in psih, ki jih povzroča srčna glista;
To prevent infection, keep away from crowded places, gargle upon returning home, and wash your hands before meals and before and after using the bathroom.
Če želite preprečiti okužbo, se izogibajte množicam, ob prihodu domov grgrajte tekočino, pred obroki ter pred in po uporabi stranišča pa si umivajte roke.
To prevent licking, apply topically to the skin restricting the area of application to the animal’s neck at the base of the skull.
Nanos na zatilje preprečuje, da bi žival zdravilo polizala.
To prevent manic episodes in adults, the same dose should be continued.
Za preprečevanje maničnih epizod pri odraslih je treba nadaljevati jemanje istega odmerka.
to prevent mortality and clinical signs caused by canine adenovirus type 1,
za preprečevanje smrtnosti in kliničnih znakov, ki jih povzroča pasji adenovirus tipa 1,
to prevent mortality and clinical signs caused by canine distemper virus,
za preprečevanje smrtnosti in kliničnih znakov, ki jih povzroča virus pasje kuge,
To prevent mortality and to reduce clinical signs and lesions of Infectious Bursal disease.
Za preprečevanje smrtnosti, ublažitev kliničnih znakov in poškodb, ki so posledica bolezni
To prevent mortality and to reduce clinical signs and lesions of Infectious Bursal disease.
Za preprečevanje smrtnosti, ublažitev kliničnih znakov in poškodb, ki so posledica bolezni Gumboro.
To prevent possible irritation of abraded skin by inadvertent contact with NexoBrid, such areas can be protected by a layer of a sterile fatty ointment.
Da preprečite možno draženje odrgnjene kože zaradi nenamernega stika z zdravilom NexoBrid, lahko te predele zaščitite s plastjo sterilnega mastnega mazila.
To prevent pregnancy, female patients using hormonal contraception are advised to use an additional or alternative method during treatment and for 4 months following discontinuation of trametinib.
Za preprečitev nosečnosti se bolnicam, ki jemljejo hormonske kontraceptive svetuje, da uporabijo dodaten ali drug način kontracepcije med zdravljenjem in še 4 mesece po prekinitvi zdravljenja s trametinibom.
to prevent seizures
za preprečevanje epileptičnih napadov
To prevent side effects, the dose of Axura is gradually increased over the first three weeks of treatment: during the first week, the dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg.
Da se preprečijo neželeni učinki, se odmerek zdravila Axura v prvih treh tednih zdravljenja postopoma povečuje: prvi teden je odmerek 5 mg; drugi teden 10 mg, tretji teden pa 15 mg.
To prevent side effects, the dose of Ebixa is gradually increased over the first three weeks of treatment: during the first week, the dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg.
Da se preprečijo neželeni učinki, se odmerek zdravila Ebixa v prvih treh tednih zdravljenja postopoma povečuje: prvi teden je odmerek 5 mg; drugi teden 10 mg, tretji teden pa 15 mg.
To prevent side effects, the dose of Marixino is gradually increased over the first three weeks of treatment: during the first week, the dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg.
Da se preprečijo neželeni učinki, se odmerek zdravila Marixino v prvih treh tednih zdravljenja postopoma povečuje: prvi teden je odmerek 5 mg; drugi teden 10 mg, tretji teden pa 15 mg.
To prevent side effects, the dose of Memantine Accord is gradually increased over the first three weeks of treatment: during the first week, the daily dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg.
Da se preprečijo neželeni učinki, se odmerek zdravila Memantine Accord v prvih treh tednih zdravljenja postopoma povečuje: prvi teden je odmerek 5 mg; drugi teden 10 mg, tretji teden pa 15 mg.
To prevent side effects, the dose of Memantine LEK is gradually increased over the first three weeks of treatment: during the first week, the dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg.
Da se preprečijo neželeni učinki, se odmerek zdravila Memantine LEK v prvih treh tednih zdravljenja postopoma povečuje: prvi teden je odmerek 5 mg, drugi teden 10 mg, tretji teden pa 15 mg.
To prevent side effects, the dose of Memantine Merz is gradually increased over the first three weeks of treatment: during the first week, the dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg.
Da se preprečijo neželeni učinki, se odmerek zdravila Memantine Merz v prvih treh tednih zdravljenja postopoma povečuje: prvi teden je odmerek 5 mg, drugi teden 10 mg, tretji teden pa 15 mg.
To prevent side effects, the dose of Memantine ratiopharm is gradually increased over the first three weeks of treatment: during the first week, the dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg.
Da se preprečijo neželeni učinki, se odmerek zdravila Memantine ratiopharm v prvih treh tednih zdravljenja postopoma povečuje: prvi teden je odmerek 5 mg, drugi teden 10 mg, tretji teden pa 15 mg.
To prevent side effects, the dose of Nemdatine is gradually increased over the first three weeks of treatment: during the first week, the dose is 5 mg; in the second week, it is 10 mg; and during the third week, it is 15 mg.
Da se preprečijo neželeni učinki, se odmerek zdravila Nemdatine v prvih treh tednih zdravljenja postopoma povečuje: prvi teden je odmerek 5 mg, drugi teden 10 mg, tretji teden pa 15 mg.
to prevent stroke and the formation of clots in adults who have an abnormal heart beat called ‘non-valvular atrial fibrillation’ and are considered to be at risk of stroke; to treat deep vein thrombosis (DVT, a blood clot in a deep vein, usually in the leg) and pulmonary embolism (PE, a clot in a blood vessel supplying the lungs), and to prevent these conditions from reoccurring in adults.
za preprečevanje kapi in nastajanja krvnih strdkov pri odraslih z motnjami srčnega utripa, imenovanimi „atrijska fibrilacija brez okvare srčnih zaklopk“, in pri katerih obstaja tveganje za kap. za zdravljenje globoke venske tromboze (DVT, krvnega strdka v globoki veni, običajno v nogi) in pljučne embolije (strdka v krvni žili, ki oskrbuje pljuča) ter za preprečevanje njune ponovitve pri odraslih.
to prevent stroke caused by a blood clot in the brain and systemic embolism (a blood clot in a blood vessel) in patients with non-valvular atrial fibrillation (irregular rapid contractions of the upper chambers of the heart); to treat deep vein thrombosis (DVT, a blood clot in a deep vein, usually in the leg) and pulmonary embolism (a clot in a blood vessel supplying the lungs), and to prevent DVT and pulmonary embolism from re-occuring. to prevent atherothrombotic events (problems caused by blood clots and hardening of the arteries) after an acute coronary syndrome.
preprečevanje kapi, ki jo povzročajo krvni strdki v možganih in sistemske embolije (krvnega strdka v žili) pri bolnikih z atrijsko fibrilacijo brez okvare srčnih zaklopk (hitrim nepravilnim krčenjem zgornjih srčnih prekatov); zdravljenje globoke venske tromboze (DVT, krvnega strdka v globoki veni, običajno v nogi) in pljučne embolije (strdka v žili, ki oskrbuje pljuča) ter preprečevanje njune ponovitve; preprečevanje aterotrombotičnih dogodkov (težav, ki jih povzročajo krvni strdki in otrdelost krvnih žil) po akutnem koronarnem sindromu.
to prevent the formation of blood clots in the veins in adults who have had an operation to replace a hip or knee;
za preprečevanje nastajanja krvnih strdkov v venah pri odraslih po operativni vstavitvi umetnega kolka ali kolena;
To prevent the possible transmission of disease, each cartridge must be used by one patient only, even if the needle on the delivery device is changed.
Da bi preprečili morebiten prenos bolezni, lahko posamezen vložek uporabite le pri enem bolniku, tudi če zamenjate iglo na pripomočku za injiciranje.
To prevent the possible transmission of disease, each cartridge must be used by one patient only, even if the needle on the delivery device is changed.
Da bi preprečili možen prenos bolezni, sme vsak vložek uporabljati en sam bolnik, tudi če zamenjate iglo na pripomočku za dovajanje.
To prevent the possible transmission of disease, each cartridge must be used by you only, even if the needle on the delivery device is changed.
Da bi preprečili možen prenos bolezni, smete vsak vložek uporabljati samo vi, tudi če zamenjate iglo na pripomočku za dovajanje.
To prevent the possible transmission of disease, each pen must be used by one patient only, even if the needle is changed.
Da bi preprečili možen prenos bolezni, sme vsak injekcijski peresnik uporabljati en sam bolnik, tudi če zamenjate iglo na pripomočku za dovajanje.
To prevent the possible transmission of disease, each pen must be used by you only, even if the needle is changed.
Da bi preprečili možen prenos bolezni, smete vsak injekcijski peresnik uporabljati samo vi, tudi če zamenjate iglo na pripomočku za dovajanje.
To prevent treatment failure, the dose of OLYSIO must not be reduced or interrupted.
Odmerjanja zdravila OLYSIO se ne sme zmanjšati ali prekinjati, da ne bi prišlo do neuspeha zdravljenja.
to prevent venous thromboembolism (blood clots that form inside the veins, obstructing blood flow), especially in patients who are having surgery or who are at greater risk of clots because they are bedridden due to illness;
preprečevanje venske trombembolije (krvnih strdkov, ki nastanejo v venah in ovirajo pretok krvi), zlasti pri bolnikih, pri katerih bo opravljen kirurški poseg ali ki jih strdki bolj ogrožajo, ker morajo zaradi bolezni ležati v postelji;
to prevent venous thromboembolism (VTE, the formation of blood clots in the veins) in patients who are undergoing surgery to replace a hip or knee;
preprečevanje venske tromboembolije (VTE, nastajanja krvnih strdkov v venah) pri bolnikih po kirurški zamenjavi kolka ali kolena;
To prime the pump, fully depress the pump mechanism repeatedly until gel is observed, then depress the pump one more time, and discard this portion of the product to assure precise dose delivery.
Črpalko napolnite tako, da večkrat popolnoma pritisnete mehanizem črpalke, dokler ne opazite gela, nato ga pritisnite še enkrat in zavrzite ta del zdravila, da zagotovite natančno dovajanje odmerka.
To prime your pen, turn the dose knob to select 2 units.
Zavrtite gumb za odmerjanje tako, da izberete 2 enoti.
To protect other people from becoming infected with hepatitis B:
Da boste druge osebe zavarovali pred okužbo s hepatitisom B:
To protect yourself and others from possible needle sticks, it is very important to throw away every syringe, with the needle attached, in the puncture-resistant container right after use.
Da sebe in druge zaščitite pred morebitnimi vbodi z iglo, je zelo pomembno, da po uporabi vsako iglo, pritrjeno na injekcijsko brizgo, zavržete v vsebnik, odporen na vbode.
To provide an estimate of the pharmacokinetic data if all patients in this age group were to receive a 1 g dose, the pharmacokinetic data were calculated adjusting for a 1 g dose, assuming linearity.
Da bi ocenili farmakokinetične podatke, kakršne bi dobili, če bi vsi bolniki v tej skupini prejeli odmerek 1 g, so farmakokinetične podatke ob predpostavki linearnosti s preračunom prilagodili za odmerek 1 g.
to provide information on the management and minimisation of anticholinergic reactions, especially on management of constipation, urinary retention, pneumonia, risk of overheating, CNS effects or overdose; and on allergic reactions.
zagotoviti informacije o obvladovanju in zmanjševanju antiholinergičnih učinkov, zlasti o ravnanju pri zaprtosti, zastajanju urina, pljučnici, tveganju pregrevanja, učinkih na centralni živčni sistem ali prevelikem odmerjanju, ter o alergičnih reakcijah.
To provide results of a double-blinded, placebo-controlled, long-term efficacy and safety study to investigate a broader primary endpoint clinically meaningful in terms of walking ability and to further evaluate the early identification of responders in order to guide further treatment based on a CHMP agreed protocol.
Zagotoviti rezultate dvojno slepe, s placebom kontrolirane študije dolgoročne učinkovitosti in varnosti za preučitev širše primarne končne točke, ki je klinično pomembna v smislu sposobnosti hoje, in za nadaljnjo ocenitev zgodnje identifikacije bolnikov, ki se odzivajo, zaradi usmeritve nadaljnjega zdravljenja na podlagi protokola, dogovorjenega s CHMP.
To provide sufficient volume to allow accurate dispensing, each vial is formulated to contain an overfill of 0.3 ml.
Zaradi zagotovitve zadostnega volumna za natančno odvzemanje imajo viale presežek, ki znaša 0,3 ml.
To provide sufficient volume to allow accurate dispensing, each vial is formulated to contain an overfill of 0.6 ml.
Zaradi zagotovitve zadostnega volumna za natančno odvzemanje imajo viale presežek, ki znaša 0,6 ml.
To qualify as LIR, in the two weeks prior to first study visit patients had to have reported concurrent OIC symptoms of at least moderate severity while taking at least one laxative class for a minimum of four days during the pre-study period.
Med bolnike z nezadostnim odzivom na odvajala so se uvrstili tisti, ki so imeli v dveh tednih pred prvim obiskom v študiji sočasne in vsaj zmerno hude simptome OIC ter so uporabljali vsaj eno skupino odvajal najmanj štiri dni med obdobjem pred študijo.
To re-attach, place the child-resistant cap on the nasal spray and turn the cap clockwise.
Za otroke varno zaporko na pršilo znova namestite tako, da zavrtite zaporko v desno.
To reconstitute and administer this product the following tools are needed: a 10 ml syringe or a syringe of a convenient size according to injection volume, alcohol swabs, the included vial adapter and an infusion set (tubing, butterfly needle).
Za pripravo in aplikacijo tega zdravila boste potrebovali: eno 10-ml brizgo (ali brizgo primerne velikosti glede na količino, ki jo morate injicirati), alkoholna zloženca, priloženi nastavek za vialo in infuzijski komplet (cevke, iglo z metuljčkom).
To reconstitute and administer this product the following tools are needed: a 10 ml syringe or a syringe of a convenient size according to injection volume, alcohol swabs, the included vial adapter and an infusion set (tubing, butterfly needle).
Za pripravo in dajanje tega zdravila boste potrebovali: eno 10-ml brizgo (ali brizgo primerne velikosti glede na količino, ki jo morate injicirati), alkoholna zloženca, priloženi nastavek za vialo in infuzijski komplet (cevke, iglo z metuljčkom).
To reconstitute lyophilised interferon beta-1b for injection, use the pre-filled syringe with solvent provided and a needle to inject the 1.2 ml of the solvent (sodium chloride solution, 5.4 mg/ml (0.54% w/v)) into the Betaferon vial.
Za rekonstitucijo liofiliziranega interferona beta-1b za injiciranje je treba v vialo z zdravilom Betaferon s priloženo napolnjeno injekcijsko brizgo z vehiklom in iglo vbrizgati 1,2 ml vehikla (raztopina natrijevega klorida 5,4 mg/ml (0,54 % m/v)).
To reconstitute the powder bring the vial to room temperature and aseptically add 10.5 mL of water for injection.
Za pripravo koncentrata prenesite vialo na sobno temperaturo in vanjo aseptično dodajte 10,5 ml vode za injekcije.
To reconstitute the vaccine, inject 3 ml of solvent into the small vial with the powder.
Za rekonstitucijo cepiva injicirajte 3 ml vehikla v vialo s praškastim delom.
To reconstitute the vaccine, inject all the solvent in the pre-filled syringe into the vial of lyophilized vaccine and gently agitate to mix thoroughly.
Pri rekonstituciji cepiva ves vehikel iz napolnjene injekcijske brizge iztisnite v vialo z liofiliziranim cepivom in z nežnim tresenjem dobro premešajte.
To reconstitute, remove the tab portion of the vial cap and clean the rubber stopper with 70% ethanol or equivalent.
Za rekonstitucijo odstranite del z zanko na pokrovčku viale in očistite kavčukovo zaporko z 70% etanolom ali ekvivalentom.
To reconstitute, use the solvent supplied.
Za pripravo cepiva uporabite priložen vehikel.
To reconstitute, withdraw of the required volume of the supplied diluent from its vial (for 20 ml vial containing 852 mg of lyophilised powder reconstitue using 10 ml of diluent, or for 5 ml vial containing 340 mg of lyophilised powder reconstitue using 4 ml of diluent) and add to the vial containing the lyophilised powder.
Za rekonstitucijo prenesite zahtevano količino vehikla iz viale z vehiklom (za 20 ml vialo, ki vsebuje 852 mg liofiliziranega praška, uporabite 10 ml vehikla, za 5 ml vialo, ki vsebuje 340 mg liofiliziranega praška, uporabite 4 ml vehikla) v vialo z liofiliziranim praškom.
To reconstitute, withdraw the required volume of the supplied diluent from its vial (for 20 ml vial containing 852 mg of lyophilised powder reconstitue using 10 ml of diluent, or for 5 ml vial containing 340 mg of lyophilised powder reconstitue using 4 ml of diluent) and add to the vial containing the lyophilised powder.
Za rekonstitucijo prenesite zahtevano količino vehikla iz viale z vehiklom (za 20 ml vialo, ki vsebuje 852 mg liofiliziranega praška, uporabite 10 ml vehikla, za 5 ml vialo, ki vsebuje 340 mg liofiliziranega praška, uporabite 4 ml vehikla) v vialo z liofiliziranim praškom.
To record the first date of prescription and the contact details of their prescriber
Zabeležiti datum začetka zdravljenja in kontaktne podatke njihovega zdravnika.
to reduce high levels of calcium in the blood (hypercalcaemia) in patients with parathyroid cancer to reduce high levels of calcium in the blood (hypercalcaemia) in patients with primary hyperparathyroidism when removal of the parathyroid gland is not possible.
za zmanjšanje zvišane koncentracije kalcija v krvi (hiperkalciemije) pri bolnikih z rakom obščitnic, za zmanjšanje zvišane koncentracije kalcija v krvi (hiperkalciemije) pri bolnikih s primarnim hiperparatiroidizmom ali če odstranitev obščitničnih (paratiroidnih) žlez ni mogoča.
To reduce mortality, clinical signs and lesions of Marek’s disease.
Za zmanjšanje smrtnosti, ublažitev kliničnih znakov in poškodb zaradi Marekove bolezni.
To reduce side effects at the start of treatment, your doctor should start you on a low dose of Betaferon and increase it gradually (see section 3. ‘How to use Betaferon’).
Za zmanjšanje neželenih učinkov na začetku zdravljenja bo vaš zdravnik začel z majhnim odmerkom zdravila Betaferon, ki ga bo postopoma povečeval (glejte poglavje 3, Kako uporabljati zdravilo Betaferon).
To reduce skin irritation, select a different part of your belly each day.
Da bi zmanjšali draženje kože, vsak dan izberite drugo mesto na trebuhu.
To reduce the amount of calcium in the blood in adult patients where it is too high due to the presence of a tumour.
Za znižanje količine kalcija v krvi pri odraslih, kadar je ta zaradi prisotnosti tumorja prevelika.
To reduce the amount of calcium in the blood in adult patients where it is too high due to the presence of a tumour.
zniževanje količine kalcija v krvi pri odraslih, kadar je ta prevelika zaradi prisotnosti tumorja.
To reduce the amount of medicine that could come into the rest of the body after application of eye drops close your eye and apply gentle pressure to the corner of the eye next to the nose with a finger for at least 2 minutes.
Da bi zmanjšali količino zdravila, ki bi lahko prišlo v druge dele telesa, po uporabi kapljic za oko zaprite oko in rahlo pritisnite s prstom na očesni kot ob nosu za najmanj 2 minuti.
To reduce the chance of infection, wipe the injection site with the other alcohol pad.
Za zmanjšanje možnosti okužbe obrišite injekcijsko mesto s priloženim alkoholnim zložencem.
To reduce the chance of side effects your doctor will prescribe the lowest dose of this combination of drugs to control your asthma or COPD.
Za zmanjšanje možnosti neželenih učinkov vam bo vaš zdravnik predpisal najmanjši odmerek te kombinacije zdravil za nadzorovanje vaše astme ali KOPB.
To reduce the chance that these symptoms might happen, you should be on a regular daily dose of your alpha-blocker before you start VIAGRA.
Da bi zmanjšali verjetnost za pojav teh simptomov, morate pred začetkom uporabe zdravila VIAGRA redno jemati dnevni odmerek antagonista adrenergičnih receptorjev alfa.
to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and the occurrence of febrile neutropenia (neutropenia with fever) in patients receiving chemotherapy (cancer treatment) that is cytotoxic (cell-killing);
za skrajšanje trajanja nevtropenije (nizke ravni nevtrofilcev, vrste belih krvničk) in zmanjšanje pojava febrilne nevtropenije (nevtropenije s povišano telesno temperaturo) pri bolnikih, ki prejemajo kemoterapijo (zdravljenje proti raku), ki je citotoksična (ubija celice);
to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and the occurrence of febrile neutropenia (neutropenia with fever) in patients receiving chemotherapy (cancer treatment) that is cytotoxic (cell-killing);
za zmanjšanje trajanja nevtropenije (nizke ravni nevtrofilcev, vrste belih krvničk) in ob pojavu febrilne nevtropenije (nevtropenije s povišano telesno temperaturo) pri bolnikih, ki jih zdravijo s kemoterapijo (zdravljenje raka), ki je citotoksična (ubija celice);
to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and the occurrence of febrile neutropenia (neutropenia with fever) in patients receiving chemotherapy (medicines to treat cancer) that is cytotoxic (cell-killing);
za skrajšanje trajanja nevtropenije (nizke ravni nevtrofilcev, vrste belih krvnih celic) in pojava febrilne nevtropenije (nevtropenije s povišano telesno temperaturo) pri bolnikih, ki se zdravijo s kemoterapijo (zdravili za zdravljenje raka), ki je citotoksična (uničuje celice);
to reduce the duration of neutropenia (low levels of neutrophils, a type of white blood cell) and the occurrence of febrile neutropenia (neutropenia with fever) in patients receiving cytotoxic chemotherapy (medicines to treat cancer by killing cells);
za skrajšanje trajanja nevtropenije (nizke ravni nevtrofilcev, ki so vrsta belih krvnih celic) in zmanjšanje pojavljanja febrilne nevtropenije (nevtropenije s povišano telesno temperaturo) pri bolnikih, ki prejemajo citotoksično kemoterapijo (zdravila za zdravljenje raka, ki ubijajo celice);
to reduce the duration of neutropenia in patients undergoing treatment to destroy the bone marrow cells before a bone marrow transplant (such as in some patients with leukaemia) if they are at a risk of long-term, severe neutropenia;
za skrajšanje trajanja nevtropenije pri bolnikih, ki se zdravijo s terapijo, katere cilj je uničenje celic kostnega mozga pred presaditvijo kostnega mozga (kot npr. pri bolnikih z levkemijo), pri katerih obstaja tveganje za dlje trajajočo hudo nevtropenijo;
to reduce the duration of neutropenia in patients undergoing treatment to destroy the bone marrow cells before a bone marrow transplant (such as in some patients with leukaemia) if they are at a risk of long-term, severe neutropenia; to increase levels of neutrophils and reduce the risk of infections in patients with neutropenia who have a history of severe, repeated infections;
za zmanjšanje trajanja nevtropenije pri bolnikih, ki prejemajo zdravljenje za uničenje celic kostnega mozga pred njegovo presaditvijo (kot npr. pri nekaterih bolnikih z levkemijo), pri katerih obstaja tveganje za dolgotrajno, hudo obliko nevtropenije; za povišanje ravni nevtrofilcev in zmanjšanje tveganja okužb pri bolnikih z nevtropenijo z anamnezo hudih, ponavljajočih se okužb;